{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:12:17Z","timestamp":1761959537204,"version":"build-2065373602"},"reference-count":8,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2015,4,30]],"date-time":"2015-04-30T00:00:00Z","timestamp":1430352000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research Reports"],"published-print":{"date-parts":[[2016]]},"DOI":"10.1016\/j.lrr.2015.11.001","type":"journal-article","created":{"date-parts":[[2015,12,4]],"date-time":"2015-12-04T03:04:19Z","timestamp":1449198259000},"page":"1-2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis"],"prefix":"10.1016","volume":"5","author":[{"given":"Burak","family":"Uz","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilhan","family":"Dolasik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.lrr.2015.11.001_bib1","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1182\/blood-2011-08-376087","article-title":"Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)","volume":"119","author":"Kantarjian","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.lrr.2015.11.001_bib2","doi-asserted-by":"crossref","first-page":"4500","DOI":"10.1158\/0008-5472.CAN-05-0259","article-title":"In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants","volume":"65","author":"O\u2019Hare","year":"2005","journal-title":"Cancer Res."},{"key":"10.1016\/j.lrr.2015.11.001_bib3","unstructured":"\u3008http:\/\/packageinserts.bms.com\/pi\/pi_sprycel.pdf\u3009"},{"key":"10.1016\/j.lrr.2015.11.001_bib4","doi-asserted-by":"crossref","first-page":"2746","DOI":"10.1056\/NEJMc0708896","article-title":"Imatinib as a possible cause of severe rhabdomyolysis","volume":"358","author":"Penel","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.lrr.2015.11.001_bib5","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.leukres.2009.11.002","article-title":"Elevations of creatine kinase in patients treated with imatinib mesylate (GleevecTM)","volume":"34","author":"Gordon","year":"2010","journal-title":"Leuk. Res."},{"key":"10.1016\/j.lrr.2015.11.001_bib6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1177\/030089161109700327","article-title":"Rhabdomyolysis from erlotinib: a case report","volume":"97","author":"Moscetti","year":"2011","journal-title":"Tumori"},{"key":"10.1016\/j.lrr.2015.11.001_bib7","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/bdrc.10030","article-title":"Biology of platelet-derived growth factors in development","volume":"69","author":"Betsholtz","year":"2003","journal-title":"Birth Defects Res. C. Embryo Today"},{"key":"10.1016\/j.lrr.2015.11.001_bib8","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/path.1414","article-title":"Platelet-derived growth factor and its receptors are related to the progression of human muscular dystrophy: an immunohistochemical study","volume":"201","author":"Zhao","year":"2003","journal-title":"J. Pathol."}],"container-title":["Leukemia Research Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048915300042?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213048915300042?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T01:07:28Z","timestamp":1761959248000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213048915300042"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":8,"alternative-id":["S2213048915300042"],"URL":"https:\/\/doi.org\/10.1016\/j.lrr.2015.11.001","relation":{},"ISSN":["2213-0489"],"issn-type":[{"type":"print","value":"2213-0489"}],"subject":[],"published":{"date-parts":[[2016]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An unexpected and devastating adverse event of dasatinib: Rhabdomyolysis","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lrr.2015.11.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2015 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}